Cube Click is offering Common Equity in its current fundraising round, with a pre-money valuation of $28.8 million and a price per share set at $3.00. This type of security allows investors to own a portion of the company, sharing in both its potential successes and risks. Common Equity does not provide the preferential treatment that Preferred Equity might offer, such as priority in dividend payments or liquidation preferences. However, it grants investors voting rights, which can be influential in company decisions.

The exit potential for startups like Cube Click in the healthcare and pharmaceuticals sector can vary significantly, often depending on achieving substantial milestones such as FDA approval, market penetration, and revenue growth. To provide a 10X return on investment, Cube Click would need to reach a post-exit valuation of approximately $288 million, assuming no dilution. Achieving this level of return could be driven by significant revenue growth, strategic partnerships, or a successful acquisition.

Cube Click operates within the U.S. AI in Dental Imaging market, which is valued at approximately $166 million and is projected to grow at a rate of 32.5% annually. This growth is primarily driven by advancements in artificial intelligence technology and an increasing demand for enhanced diagnostic capabilities in dental care. The integration of AI into dental imaging can streamline processes, improve diagnostic accuracy, and support preventive care, aligning with broader trends toward precision medicine and technology-driven healthcare solutions.

The market trends present both opportunities and challenges for Cube Click. The positive impact includes potential market expansion as dental practices adopt AI technologies to enhance service offerings and differentiate themselves in a competitive healthcare environment. However, the rapid technological advancements also mean that Cube Click must continuously innovate and update its product offerings to maintain relevance and competitive advantage.

Cube Click's SMILE Dx platform targets a specific niche within the broader dental market—dental practices seeking to leverage AI for improved diagnostic accuracy. While the product appeals to a defined segment, the growing acceptance of AI in healthcare could expand the addressable market over time. As AI becomes more integrated into standard practice, the potential customer base for Cube Click's offerings could expand beyond early adopters to a more mainstream audience.

Cube Click is led by Dr. Richard Ricci who has run his own dental practice for over 30 years in New York City. He received his D.D.S. in Dentistry from New York University and B.A. from Brooklyn College in Biology. He holds a fellowship at the Academy of General Dentistry. 

He is joined by Dr. Andrea Cambria (CFO) also co-owns the dentistry with Dr. Ricci has been a dentist for over 30 years as well. She also holds her D.D.S from NYU and BA in Biology from Brooklyn College. 

The founders are closely advised by a team of consultants from Innolotics, a Texas-based firm specializing in helping medical device software achieve FDA clearance.

Cube Click distinguishes itself within the dental AI imaging market through its SMILE Dx platform, which focuses on enhancing diagnostic accuracy and preventive care. In this space, notable competitors include companies like Overjet, VideaHealth and Pearl, both of which offer AI-driven dental imaging solutions.

SmileDx outperforms its competitors by leveraging cutting-edge nnU-Net technology and a more comprehensive dental X-ray dataset, resulting in superior sensitivity and specificity for dental pathology detection. Unlike Overjet, which primarily caters to large Dental Service Organizations, SmileDx is accessible to dental practices of all sizes. It offers more advanced instance segmentation compared to Pearl's older bounding box technology, and provides broader diagnostic capabilities than Videa Health's limited bitewing X-ray approval. SmileDx's pending FDA approval for its state-of-the-art technology positions it as a groundbreaking solution that combines unmatched diagnostic accuracy with ease of interpretation, making it the ideal choice for dentists seeking to enhance their practice with AI-powered diagnostics.

Cube Click has shown significant revenue growth over the past year, with annual revenue increasing from $148k to $268.7k. This represents an 81.6% year-over-year growth rate, indicating a positive trend in the company's ability to generate sales. However, all of this revenue has been from consulting services provided by the founders, not from any sales of the SmileDx product. For all intents and purposes, Cube Click is a pre-revenue company. 

The most recent monthly burn rate is approximately $150k, while the cash on hand is around $16.8k. This financial position suggests a limited runway, necessitating either increased revenue generation or additional fundraising to maintain operations. The high monthly burn relative to cash reserves underscores the urgency for Cube Click to either secure more capital or achieve faster revenue growth to sustain its business activities.

There are several large competitors in this space, including Overjet AI, Pearl, and Videa Health. These competitors have FDA approved products and have raised large rounds of funding. While competing with well-funded competitors will always be difficult, Cube Click differentiates using cutting-edge technology and focuses on accessibility for all dentists, from solo practitioners to DSOs. Another risk, as is the case with any medical technology company requiring FDA clearance, there is always a chance that Cube Click incurs significant costs from delays in its approval process. This is unfortunately quite common for companies requiring FDA approval and is a risk that Cube Click will need to manage as they move through that process. Finally, the company is currently burning $150K per month, indicating the requirement of additional capital infusions into the company in order to continue operating.

Specialized artificial intelligence is poised to dominate most major industries today. Practitioners not utilizing the latest AI/ML software will likely fall behind in providing the best care for patients. Cube Click targets an industry still stuck in the 1900s using the same X-ray technology that has barely been improved in over a century of dentistry. By utilizing AI trained on prior dental X-rays, Cube Click will provide unparalleled accuracy for dentists to diagnose cavities, root canals, and gum disease. Cube Click has been awarded six patents and has two more pending, protecting its AI-technology from competitors. The company is well on its way to FDA clearance, having now submitted its 510(k) application to the FDA and projecting approval in mid-2025. While the company has several well-funded competitors, SmileDx outperforms them by leveraging cutting-edge nnU-Net technology and a more comprehensive dental X-ray dataset, resulting in superior sensitivity and specificity for dental pathology detection.

There are several large competitors in this space, including Overjet AI, Pearl, and Videa Health. These competitors have FDA approved products and have raised large rounds of funding. While competing with well-funded competitors will always be difficult, Cube Click differentiates using cutting-edge technology and focuses on accessibility for all dentists, from solo practitioners to DSOs. Another risk, as is the case with any medical technology company requiring FDA clearance, there is always a chance that Cube Click incurs significant costs from delays in its approval process. This is unfortunately quite common for companies requiring FDA approval and is a risk that Cube Click will need to manage as they move through that process. Finally, the company is currently burning $150K per month, indicating the requirement of additional capital infusions into the company in order to continue operating.

Cube Click operates in the healthcare and pharmaceuticals sector, focusing on dental AI imaging with its SMILE Dx platform. The company targets dental practices and clinics that seek to enhance diagnostic capabilities through advanced technology.

From a financial perspective, Cube Click offers Common Equity with a pre-money valuation of $28.8 million and a price per share of $3.00. The company's revenue has grown by 81.6% year-over-year, reaching $268.7k. However, the high revenue multiple of 107.2x suggests potential overvaluation, and the company's limited cash reserves of $16.8k against a monthly burn of $150k highlight financial constraints.

The U.S. AI in Dental Imaging market, valued at $166 million, is growing at a rate of 32.5% annually. Cube Click differentiates itself by focusing on preventive care within this niche. Competitors like VideaHealth and Pearl pose challenges, but Cube Click's emphasis on early diagnostics sets it apart. The target demographic includes technologically progressive dental practices looking to integrate AI solutions.

Bullish factors include the company's strong revenue growth and the expanding market for AI in dental imaging, which presents opportunities for increased adoption. Conversely, bearish factors focus on financial constraints and competitive pressures. These elements could inhibit growth if not addressed effectively.